Back to the main directory
EarningsReview / Equity
- Pareto Bank (Buy, TP: NOK65.00) - On course for another solid quarter by DnB Markets
- Storebrand (Buy, TP: NOK110.00) - Minor model adjustment by DnB Markets
- Stolt-Nielsen (Buy, TP: NOK176.00) - Extended tank container cycle by DnB Markets
- Evolution (Buy, TP: SEK1900.00) - The year of the product by DnB Markets
- Swedish Orphan Biovitrum (Hold, TP: SEK193.00) - Decent finish to a turbulent year by DnB Markets
- Grieg Seafood (Buy, TP: NOK105.00) - Strong Q4 expected by DnB Markets
- Atlantic Sapphire (Buy, TP: NOK60.00) - 2022e more back-end loaded by DnB Markets
- Bonava (Buy, TP: SEK105.00) - Ups and downs impacting Q4, but the potential upside remains by DnB Markets
- Ncc (Buy, TP: SEK190.00) - Margin growth set to continue by DnB Markets
- Peab (Buy, TP: SEK120.00) - Still attractive risk/reward by DnB Markets
- Veidekke (Buy, TP: NOK150.00) - Still seeking M&A growth by DnB Markets
- Aker Biomarine (Hold, TP: NOK45.00) - Set for growth in 2022e by DnB Markets
- Norway Royal Salmon (No_rec, TP: NOK) - Minor model update by DnB Markets
- PhotoCure (Buy, TP: NOK155.00) - Waiting for new BLC in the US by DnB Markets
- Stora Enso (Buy, TP: EUR20.00) - Pricing power and ample potential by DnB Markets
- 2020 Bulkers Minor model adjustments by DnB Markets
- Seafood - Fat Trout Weekly by DnB Markets
- Changes ahead on the new EU Green Deal White Paper by DnB Markets
- Management changes, potential catalysts, and raised guidance by DnB Markets
- A large lease, insider purchases, and raised construction sector outlook by DnB Markets
- Renaissance BioScience - RNAi technology from bioengineered yeast by Edison Investment Research
- ITS WHA...? An automated future! by BNP Paribas Exane
- Odfjell SE (Buy, TP: NOK44.00) - Steadily improving by DnB Markets
- Deployment of savings: the $2.5T question by BNP Paribas Exane
- Q1 22: A good start to the year by BNP Paribas Exane
- Trelleborg (Buy, TP: SEK285.00) - Better than ever by DnB Markets
- Swedish Orphan Biovitrum (Hold, TP: SEK193.00) - Decent finish to a turbulent year by DnB Markets
- Chr. Hansen (Buy, TP: DKK620.00) - Turning a corner: upgraded to BUY by DnB Markets
- Elektroimportøren (Buy, TP: NOK95.00) - Strong Q4e on tough comparables by DnB Markets
- Norway Royal Salmon (No_rec, TP: NOK) - Acquiring SalmoNor by DnB Markets
- Topdanmark (Hold, TP: DKK390.00) - Strong Q4e set to support dividends by DnB Markets
- AF Gruppen (Sell, TP: NOK130.00) - High valuation and consensus risk by DnB Markets
- Jm Ab (Sell, TP: SEK324.00) - High valuation post speculation by DnB Markets
- NRC Group (Buy, TP: NOK40.00) - Looking for recovery confirmation by DnB Markets
- Skanska (Hold, TP: SEK235.00) - Q4e upside potential versus consensus, but 2022e downside by DnB Markets
- YIT (Buy, TP: EUR6.00) - Still a margin-recovery case by DnB Markets
- Sandvik (Buy, TP: SEK290.00) - More to come by DnB Markets
- SalMar (Buy, TP: NOK650.00) - Minor model update by DnB Markets
- UPM (Buy, TP: EUR42.00) - Milestone year in 2022e by DnB Markets
- Topdanmark (Hold, TP: DKK390.00) - Solid underlying performance by DnB Markets
- Seafood - Fat Trout Weekly by DnB Markets
- Generous dividends ahead by DnB Markets
- Weekly news, topics & discussion by DnB Markets
- The weekly navigator by DnB Markets
- Weekly news, topics & discussion by DnB Markets
- Scandion Oncology - Drug-resistant cancer solutions by Edison Investment Research
- GSK CH: An unhealthy transaction by BNP Paribas Exane
- In-line 1Q22, with self-help recovery appeal by BNP Paribas Exane
- Value appeal, but cautious on 2022 recovery by BNP Paribas Exane
- Pulike (603566 CH) by HSBC